LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,091 | -24.0% | 28,043 | -9.2% | 0.00% | – |
| Q2 2023 | $43,556 | -6.0% | 30,891 | 0.0% | 0.00% | – |
| Q1 2023 | $46,337 | +50.6% | 30,891 | +17.5% | 0.00% | – |
| Q4 2022 | $30,760 | +2.5% | 26,291 | -0.3% | 0.00% | – |
| Q3 2022 | $30,000 | -28.6% | 26,368 | +0.3% | 0.00% | – |
| Q2 2022 | $42,000 | +7.7% | 26,302 | +2.8% | 0.00% | – |
| Q1 2022 | $39,000 | -32.8% | 25,581 | +8.5% | 0.00% | – |
| Q4 2021 | $58,000 | -9.4% | 23,581 | -7.7% | 0.00% | – |
| Q3 2021 | $64,000 | -9.9% | 25,558 | +2.2% | 0.00% | – |
| Q2 2021 | $71,000 | -74.1% | 25,000 | -78.5% | 0.00% | -100.0% |
| Q1 2021 | $274,000 | +33.7% | 116,453 | 0.0% | 0.00% | – |
| Q4 2020 | $205,000 | +88.1% | 116,453 | -0.0% | 0.00% | – |
| Q3 2020 | $109,000 | -9.9% | 116,454 | -16.0% | 0.00% | – |
| Q2 2020 | $121,000 | +39.1% | 138,697 | +31.9% | 0.00% | – |
| Q1 2020 | $87,000 | -48.5% | 105,116 | -44.5% | 0.00% | -100.0% |
| Q4 2019 | $169,000 | -15.9% | 189,367 | -7.7% | 0.00% | 0.0% |
| Q3 2019 | $201,000 | – | 205,182 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $28,160,000 | 3.29% |
| Defender Capital, LLC. | 4,416,590 | $3,657,000 | 2.67% |
| Prescott General Partners LLC | 1,851,851 | $1,534,000 | 0.13% |
| Laidlaw Wealth Management LLC | 107,379 | $89,000 | 0.06% |
| Northeast Financial Consultants Inc | 523,756 | $434,000 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $37,000 | 0.04% |
| DAFNA Capital Management LLC | 95,000 | $79,000 | 0.03% |
| Summit X, LLC | 30,700 | $25,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 529,039 | $438,000 | 0.01% |
| Keudell/Morrison Wealth Management | 10,105 | $8,000 | 0.01% |